Last reviewed · How we verify
NCT04135677
Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
Phase 4 trial testing Rivaroxaban in Left Atrial Appendage Thrombosis in 826 participants. Status unknown.
1 October 2024
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 826 |
| Start date | 11 November 2022 |
| Primary completion | 1 October 2024 |
| Estimated completion | 30 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rivaroxaban (rivaroxaban) — full drug profile →
- DAPT — full drug profile →
Conditions studied
- Left Atrial Appendage Thrombosis — all drugs for Left Atrial Appendage Thrombosis →
- Thrombi — all drugs for Thrombi →
- Stroke — all drugs for Stroke →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 85, any sex, with Left Atrial Appendage Thrombosis or Thrombi. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to assess the efficacy and safety different dosage of rivaroxaban application versus dual antiplatelet therapy after successful closure of left atrial appendage using the LAMBRE device.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Indications, evidence, and controversy in the closure of the left atrial appendage.
Patti G, Ghiglieno C. · · 2023 · cited 2× · PMID 37091645 · DOI 10.1093/eurheartjsupp/suad091
Verify or expand the search:
- PubMed search for NCT04135677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban
Trials testing the same drug.
- NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
- NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
- NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting
Other recruiting trials for Left Atrial Appendage Thrombosis
Currently open trials in the same condition.
- NCT06585228 — Detecting Cardiac Thrombi in Acute Ischemic Stroke on Cardiac CT Versus Transoesophageal Echocardiography · recruiting
- NCT06007872 — Intracardiac Echocardiography Guided Watchman Device Implant · NA · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04135677 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 15 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing